Class summary at a glance.

Every drug in the Serotonin Reuptake Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $508.3Mcombined across class
Total Rx claims: 41.1M10.7M unique beneficiaries
Generic mfrs (active): 54across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Escitalopram Oxalate

Brand: Escitalopram · 19.2M Part D claims (CY24) · 5.1M beneficiaries · First FDA approval: 2012-04-03

14 generic mfrs

Low NADAC$0.041

→

Avg plan cost$0.059

Part D spend $245.8M 1× spread, current vs floor

Class share

48%

of class CY24 spend

View profile →

Fluoxetine

Brand: FLUOXETINE · 11.3M Part D claims (CY24) · 2.8M beneficiaries · First FDA approval: 1988-02-01

24 generic mfrs 0 plans require PA

Low NADAC$0.030

→

Avg plan cost$0.694

Part D spend $148.8M 23× spread, current vs floor

Class share

29%

of class CY24 spend

View profile →

Citalopram Hydrobromide

Brand: Citalopram · 10.0M Part D claims (CY24) · 2.7M beneficiaries · First FDA approval: 2004-10-28

9 generic mfrs 0 plans require PA

Low NADAC$0.026

→

Avg plan cost$0.049

Part D spend $78.3M 2× spread, current vs floor

Class share

15%

of class CY24 spend

View profile →

Fluvoxamine

645K Part D claims (CY24) · 109K beneficiaries · First FDA approval: 2000-11-29

7 generic mfrs 0 plans require PA

Low NADAC$0.180

→

Avg plan cost$1.87

Part D spend $35.4M 10× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.